TCBI:NASDAQTexas Capital Bancshares, Inc. Analysis
Data as of 2026-05-28 - not real-time
$98.14
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Texas Capital Bancshares posted a 15.5% revenue increase year‑over‑year to $324 million and a non‑GAAP EPS of $1.58, topping consensus by 12.4%, underscoring the momentum highlighted in the recent earnings beat. Operating margins sit at 32% and net profit margins at 28.7%, reflecting strong profitability for a regional bank. The stock trades at a forward P/E of 11.7, well below the industry average of 16.6, while the price‑to‑book ratio of 1.30 suggests a modest premium to book value. Technicals are supportive: the price of $98.14 is above the 200‑day SMA ($92.75) and the MACD histogram is positive, indicating a bullish tilt despite a neutral RSI of 47.5. Support sits at $94.06 with resistance near $103.29, offering a clear upside corridor, and the 30‑day volatility of 25% is manageable given the company’s strong balance sheet (cash $2.93 bn vs debt $0.92 bn).
The DCF‑derived fair value of $235.33 implies a substantial undervaluation, and the modest 0.8% dividend appears sustainable given the net‑cash position and zero payout ratio. Market sentiment is extremely bullish (Fear‑Greed Index 92), yet the stock’s beta (~1.2) and stable volume suggest that price swings will be contained, making TCBI an attractive entry for investors seeking a blend of growth and value in the regional banking sector.
The DCF‑derived fair value of $235.33 implies a substantial undervaluation, and the modest 0.8% dividend appears sustainable given the net‑cash position and zero payout ratio. Market sentiment is extremely bullish (Fear‑Greed Index 92), yet the stock’s beta (~1.2) and stable volume suggest that price swings will be contained, making TCBI an attractive entry for investors seeking a blend of growth and value in the regional banking sector.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Q1 earnings beat and 15.5% revenue growth
- Bullish MACD signal and price above 200‑day SMA
- Upside potential to $103.29 resistance level
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- PE ratio of 13.2 versus industry 16.6 indicating valuation discount
- Strong cash position ($2.93 bn) versus modest debt ($0.92 bn)
- Consistent dividend yield and sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value of $235.33 suggests long‑term upside
- Stable operating margins and solid ROE (~10%)
- Strategic leadership appointments supporting growth trajectory
Key Metrics & Analysis
Financial Health
Revenue Growth16.90%
Profit Margin28.67%
P/E Ratio13.2
ROE10.15%
ROA1.10%
P/B Ratio1.3
Op. Cash Flow$447.3M
Industry P/E16.6
Technical Analysis
TrendBullish
RSI47.5
Support$94.06
Resistance$103.29
MA 20$98.91
MA 50$98.48
MA 200$92.75
MACDBullish
VolumeStable
Fear & Greed Index92.34
Valuation
Fair Value$235.33
Target Price$107.69
Upside/Downside9.73%
GradeUndervalued
TypeBlend
Dividend Yield0.80%
Risk Assessment
Beta1.17
Volatility25.43%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.